152 related articles for article (PubMed ID: 31684167)
1. Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response.
Itami-Matsumoto S; Hayakawa M; Uchida-Kobayashi S; Enomoto M; Tamori A; Mizuno K; Toyoda H; Tamura T; Akutsu T; Ochiya T; Kawada N; Murakami Y
Biomedicines; 2019 Nov; 7(4):. PubMed ID: 31684167
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA expression in hepatocellular carcinoma after the eradication of chronic hepatitis virus C infection using interferon therapy.
Tamori A; Murakami Y; Kubo S; Itami S; Uchida-Kobayashi S; Morikawa H; Enomoto M; Takemura S; Tanahashi T; Taguchi YH; Kawada N
Hepatol Res; 2016 Mar; 46(3):E26-35. PubMed ID: 25788219
[TBL] [Abstract][Full Text] [Related]
3. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals.
Öksüz Z; Gragnani L; Lorini S; Temel GÖ; Serin MS; Zignego AL
J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623439
[TBL] [Abstract][Full Text] [Related]
5. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
[TBL] [Abstract][Full Text] [Related]
6. Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy.
Konjeti VR; John BV
Curr Treat Options Gastroenterol; 2018 Jun; 16(2):203-214. PubMed ID: 29569093
[TBL] [Abstract][Full Text] [Related]
7. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
[TBL] [Abstract][Full Text] [Related]
8. Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals.
Pascut D; Cavalletto L; Pratama MY; Bresolin S; Trentin L; Basso G; Bedogni G; Tiribelli C; Chemello L
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717959
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients.
Merchante N; Rodríguez-Arrondo F; Revollo B; Merino E; Ibarra S; Galindo MJ; Montero M; García-Deltoro M; Rivero-Juárez A; Téllez F; Delgado-Fernández M; Ríos-Villegas MJ; García MA; Vera-Méndez FJ; Ojeda-Burgos G; López-Ruz MA; Metola L; Omar M; Alemán-Valls MR; Aguirrebengoa K; Portu J; Raffo M; Macías J; Pineda JA;
AIDS; 2018 Jul; 32(11):1423-1430. PubMed ID: 29596108
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
[TBL] [Abstract][Full Text] [Related]
14. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.
Tani J; Morishita A; Sakamoto T; Takuma K; Nakahara M; Fujita K; Oura K; Tadokoro T; Mimura S; Nomura T; Yoneyama H; Kobara H; Himoto T; Tsutsui A; Senoh T; Nagano T; Ogawa C; Moriya A; Deguchi A; Takaguchi K; Masaki T
Oncol Lett; 2020 Mar; 19(3):2205-2212. PubMed ID: 32194718
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.
Tahata Y; Sakamori R; Urabe A; Yamada R; Ohkawa K; Hiramatsu N; Hagiwara H; Oshita M; Imai Y; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2020 Oct; 50(10):1118-1127. PubMed ID: 32678925
[TBL] [Abstract][Full Text] [Related]
18. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S
J Hepatol; 2016 Oct; 65(4):727-733. PubMed ID: 27349488
[TBL] [Abstract][Full Text] [Related]
19. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.
Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Yoshitomi M; Mikagi K; Saitsu H
Hepatol Int; 2018 Mar; 12(2):149-157. PubMed ID: 29488056
[TBL] [Abstract][Full Text] [Related]
20. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus.
Yasui Y; Kurosaki M; Komiyama Y; Takada H; Tamaki N; Watakabe K; Okada M; Wang W; Shimizu T; Kubota Y; Higuchi M; Takaura K; Tsuchiya K; Nakanishi H; Takahashi Y; Itakura J; Enomoto N; Izumi N
Hepatol Res; 2018 Dec; 48(13):1131-1139. PubMed ID: 30030872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
